Purpose: To report the treatment of therapy-resistant Pseudomonas aeruginosa keratitis with topical piperacillin/ tazobactam. Methods: Retrospective report of 3 cases. Results: Three patients with P. aeruginosa keratitis were unresponsive to various antimicrobials. Resolution of all 3 cases of keratitis occurred upon commencement of topical piperacillin/tazobactam. Conclusion: Therapy-resistant P. aeruginosa keratitis acquired from the community is becoming an increasing problem. Topical piperacillin/tazobactam is an option for the treatment of therapy-resistant P. aeruginosa keratitis.
Introduction W e report 3 cases of community-acquired, therapyresistant Pseudomonas aeruginosa keratitis. The predisposing factors, treatment with piperacillin/tazobactam, and sequelae are discussed.
Case Reports

Case 1
A 34-year-old man presented with a painful and injected right eye after sand particles had entered his eye a week earlier. Best-corrected visual acuity was hand movement in his right eye. On slit-lamp examination, a central corneal ulcer measuring 4.5 mm × 6.0 mm was seen ( Fig. 1A ) . There was no hypopyon. He was commenced on topical ciprofl oxacin 0.3% and gentamicin 1.4% hourly.
On the third day, a hypopyon was noted with increasing stromal infi ltrate. Corneal scraping culture at Day 3 revealed P. aeruginosa . On the same day (Day 3 of treatment), ciprofl oxacin and gentamicin were stopped and daily subconjunctival ceftazidime 100 mg, hourly topical ceftazidime 5%, and gatifl oxacin 0.3% were initiated. No improvement was noted. After 5 days, daily oral fl uconazole 200 mg and hourly topical fl uconazole 1% and natamycin 5% were added. Repeat corneal scrapings were negative. The ulcer remained unresponsive and after 5 days, ceftazidime (both topical and subconjunctival) was replaced with hourly topical piperacillin/ tazobactam 10%. Rapid contraction of the stromal abscess occurred within 24 h of treatment. The dosage of gatifl oxacin, natamycin, and fl uconazole was reduced to 6 hourly and stopped after 1 week of piperacillin/tazobactam commencement. Piperacillin/tazobactam was reduced to 2 h, 4 h, and then 6 h in weekly intervals and stopped after 1 month upon resolution of the keratitis. Patient's fi nal best-corrected visual acuity for his right eye was 6/24.
Case 2
A 48-year-old man complained of sudden onset of left eye foreign body sensation and decreased vision. Ophthalmic examination revealed visual acuity of 6/60 and a central corneal ulcer measuring 3 mm × 4 mm in his left eye ( Fig.  1B ) . A hypopyon of 1.5 mm was noted. He was started on hourly topical ciprofl oxacin 0.3% and gentamicin 1.4%. No improvement of the keratitis was noted. At Day 3 of therapy, the corneal scraping culture grew P. aeruginosa and topical ciprofl oxacin and gentamicin were stopped. Hourly topical ceftazidime 5% and daily subconjunctival ceftazidime were started. The keratitis improved. On Day 10 of treatment, however, the hypopyon increased with enlargement of the stromal infi ltrate. Ceftazidime was stopped and the patient was started on hourly topical cefoperazone 5%, hourly topical amikacin 2%, and daily subconjunctival amikacin 25 mg. Repeated corneal scraping cultures were negative. The keratitis remained unresponsive to cefoperazone and amikacin. 
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choice for P. aeruginosa keratitis. In recent years, P. aeruginosa has become increasingly resistant toward fl uoroquinolones and other antimicrobials. 2 , 3 It is reported that the increased use of fl uoroquinolones in hospitals and their surrounding community was associated with increased rates of fl uoroquinolone-resistant P. aeruginosa infections. 4 In addition, previous ciprofl oxacin exposure was documented to cause the highest incidence of multidrug-resistant P. aeruginosa compared with other classes of antimicrobials. 5 All cases were community-acquired and responded poorly to fl uoroquinolones, aminoglycosides, and cephalosporins. This may be indicative of widespread use of fl uoroquinolones in the community, leading to the development of therapy-resistant P. aeruginosa strains.
In all 3 cases, the isolate was identifi ed as P. aeruginosa via microscopic examination of the organism cultured on blood agar plates in nutrient broth (observation for characteristic fruity odor and colonial forms of P. aeruginosa ), Gram-staining (Gram-negative, nonfermentative rods), evidence of pigment production (detection of fl uorescent colonies in a dark chamber with ultraviolet light and evidence of pyocyanin production via culture with Pseudomonas Agar P [Difco]), and the presence of cytochrome oxidase activity using α-naphthol solution and p -aminodimethylaniline oxalate. The identities of the isolates were confi rmed on Day 3 after the corneal scraping was taken. It is interesting to note that the clinical response of the corneal ulcers differed signifi cantly in comparison with the corneal scraping sensitivity results ( Table 1 ). In view all 3 isolates were sensitive to all antimicrobials in vitro but resistant to all antimicrobials in vivo except for piperacillin/tazobactam; we believe the strains to be therapy-resistant P. aeruginosa . In addition, the isolates could have developed resistance to the antimicrobials along the course of treatment. This could be secondary to different levels of P. aeruginosa drug resistance due to different minimum inhibitory concentrations (MICs) of antimicrobials in the patient's corneas. MIC was not performed at the time of management of keratitis as our survey of cases was retrospective. However, Kirby-Bauer antibiotic testing (disc diffusion method) was used to determine antibiotic sensitivity of bacterial isolates in all 3 cases. This method showed that all isolated P. aeruginosa strains were fully susceptible to the antimicrobials tested in Table 1 . We suggest that the difference between in vitro susceptibility and clinical response may be because documented in vitro resistance may not be representative of true clinical resistance. This is because keratitis resolution is dependent on various host factors and drug corneal penetration. 6 Hence, the clinical response of keratitis to the antibiotic should be the fi rst guideline of therapy instead of corneal scraping sensitivity results. 7 The double disc synergy test (standard disc diffusion assay on Mueller-Hinton agar) revealed positive β-lactamase expression for all 3 cases. The presence of β-lactamase expression may further explain the resolution of keratitis with piperacillin/tazobactam as piperacillin is a broad spectrum ureidopenicillin and tazobactam is a triazolymethyl penicillanic acid sulfone β-lactamase inhibitor. The combination of these 2 drugs results in an extended-spectrum antibiotic, which is effective for Gram-negative, Gram-positive, and anaerobic bacteria. 
Case 3
A 17-year-old boy presented with a right painful and injected eye after tar particles entered his eye a week earlier. Visual acuity of his right eye was light perception and a central corneal ulcer measuring 8.2 mm × 7.8 mm was seen. There was a hypopyon measuring 2 mm ( Fig. 1C ) . He was commenced on hourly topical ciprofl oxacin 0.3% and gentamicin 1.4%. No improvement was noted and corneal scraping culture revealed P. aeruginosa . At Day 3 of treatment, ciprofl oxacin and gentamicin were stopped and the patient was started on daily subconjunctival ceftazidime 100 mg and hourly topical ceftazidime 5%. The ulcer did not improve and repeated corneal scrapings were negative. After 5 days of treatment, ceftazidime was stopped and hourly topical piperacillin/tazobactam 10% monotherapy was commenced. Contraction of the ulcer occurred within 3 days and piperacillin/tazobactam was reduced to 2 h after 5 days of piperacillin/tazobactam monotherapy. The dosage was tapered off in 2 h intervals (4, 6, and 8 h) every week and stopped after 3 weeks of therapy when the keratitis resolved. The patient had a fi nal visual acuity of hand movement in his right eye due to dense corneal scarring.
Discussion
P. aeruginosa is a ubiquitous, opportunistic organism that inhabits soil and water. This Gram-negative bacterium that colonizes intact corneal epithelium is a common cause of microbial keratitis.
1 Predisposing factors include a previous history of trauma or contact lens wear. Out of the 3 cases, 2 were trauma-related while 1 occurred spontaneously. The patients had no medical illnesses and denied hospitalization or prolonged antibiotic exposure (systemic or topical). In all 3 cases, no corticosteroids (topical or oral) were given.
Treatment of P. aeruginosa keratitis is challenging due to its ever-evolving resistance toward antimicrobials. Resistance mechanisms of P. aeruginosa include a protective outer membrane of lipopolysaccarides, a tendency to colonize in biofi lm form and innate possession of antibioticresistant plasmids. Among the various anti-pseudomonal agents available, fl uoroquinolones are the usual treatment of fl uoroquinolones. 5 Aminoglycosides are inactivated by P. aeruginosa via enzymatic transfer of acetyl, phosphate, or adenyl groups to amino and hydroxyl substituents. 9 The combination of piperacillin/tazobactam was effective in all 3 cases as this combination of antimicrobials is not inactivated via extended-spectrum plasmid-mediated enzymes and confers protection against P. aeruginosa resistance. 5 Piperacillin has been suggested as a possible choice of anti-pseudomonal treatment for multidrug-resistant P. aeruginosa keratitis. 7 Limited information, however, exists regarding the treatment of P. aeruginosa keratitis with piperacillin/tazobactam. In addition, ocular and systemic side effects of topical ocular piperacillin/tazobactam are not well described. In all 3 cases, no ocular or systemic side effects were observed with topical piperacillin/tazobactam therapy. For case 1, gatifl oxacin, natamycin, and fl uconazole were tapered off within a week upon commencement of piperacillin/tazobactam and the keratitis continued to improve with piperacillin/tazobactam monotherapy. In cases 2 and 3, there was no overlap between the treatments. Hence, we believe that keratitis resolution in all 3 cases was the result of piperacillin/tazobactam monotherapy and not due to additive or synergistic effects of multiple antimicrobials.
All 3 cases required 1 month of treatment with piperacillin/tazobactam for the complete resolution of pseudomonal keratitis. Two of the 3 cases had some visual improvement after treatment but all 3 cases had a fi nal visual acuity of <6/18. This was caused by dense corneal scarring secondary to massive liquefactive necrosis by P. aeruginosa . Cases 2 and 3 would require penetrating keratoplasty for further visual rehabilitation.
In conclusion, increased vigilance is necessary for prompt identifi cation of community-acquired therapy-resistant P. aeruginosa keratitis. Topical piperacillin/tazobactam is an option for the treatment of therapy-resistant P. aeruginosa keratitis.
